drugset / Trial / NCT03790072
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
NaSequentialOpen-labelTreatment
Summary
This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.
Timeline
- Start
- 2018-11-27
- Primary completion
- 2021-03-26
- Completion
- 2021-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OmnImmune® | Cell therapy | 1e+06 cells/kg | — |
| Subject | OmnImmune® | Cell therapy | 1e+07 cells/kg | — |
| Subject | OmnImmune® | Cell therapy | 1e+08 cells/kg | — |